The Corporation's first technology platform is based on a transdermal carrier designed to deliver drugs through the skin directly to the disease site. Unlike oral medications, Nuvo's transdermal products do not rely on bloodstream circulation to reach affected parts of the body. Drugs built on this platform offer site-specific treatment while limiting exposure to potentially harmful levels of chemical agents.

Under the leadership of the new Board and management, there has been an increased focus on developing an improved form of this drug delivery technology. The Corporation is currently developing a family of improved skin penetration enhancers, with a number of formulations in the preclinical stage. The new penetration enhancers are designed to expand the Corporation's drug carrier technology and to increase safety and user compliance.

The Company is researching a number of different carriers and drug-carrier combinations through fqubed Inc., our U.S. based research and development facility that has the capability to solve skin delivery and anti-delivery problems by utilizing high-throughput experimentation systems that screen different soft material formulations based on their affect on skin. These candidates represent opportunities to change the method of administration for proven drugs from oral to topical.

Changing dosage form from oral to topical provides the possibly of reduced dosage and fewer side effects. The transdermal expertise acquired through Pennsaid^® development, positions the company to create even safer and more effective topical products and it intends to leverage its skin-penetrating technologies to create a portfolio of transdermal products targeting a variety of indications.